These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 8018961)

  • 21. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy.
    Yang XD; Jia XC; Corvalan JR; Wang P; Davis CG; Jakobovits A
    Cancer Res; 1999 Mar; 59(6):1236-43. PubMed ID: 10096554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
    Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
    Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-EGFR monoclonal antibodies which act as EGF, TGF alpha, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours.
    Modjtahedi H; Komurasaki T; Toyoda H; Dean C
    Int J Cancer; 1998 Jan; 75(2):310-6. PubMed ID: 9462724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth inhibition of xenotransplanted human carcinomas by a monoclonal antibody directed against the epidermal growth factor receptor.
    Schnürch HG; Stegmüller M; Vering A; Beckmann MW; Bender HG
    Eur J Cancer; 1994; 30A(4):491-6. PubMed ID: 8018408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-tumor efficacy of an anti-epidermal-growth-factor-receptor monoclonal antibody and its F(ab')2 fragment against high- and low-EGFR-expressing carcinomas in nude mice.
    Tosi E; Valota O; Negri DR; Adobati E; Mazzoni A; Meazza R; Ferrini S; Colnaghi MI; Canevari S
    Int J Cancer; 1995 Sep; 62(5):643-50. PubMed ID: 7665239
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of a bifunctional monoclonal antibody directed against a tumor marker and doxorubicin on the growth of epidermoid vulvar carcinoma grafted in athymic mice.
    Morelli D; Ménard S; Pozzi B; Balsari A; Colnaghi MI
    Cell Biophys; 1994; 24-25():119-26. PubMed ID: 7736515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type I receptor tyrosine kinases as targets for therapy in breast cancer.
    Baselga J; Mendelsohn J
    J Mammary Gland Biol Neoplasia; 1997 Apr; 2(2):165-74. PubMed ID: 10882302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
    Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
    Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytotoxicity against human tumor cells mediated by the conjugate of anti-epidermal growth factor receptor monoclonal antibody to recombinant ricin A chain.
    Masui H; Kamrath H; Apell G; Houston LL; Mendelsohn J
    Cancer Res; 1989 Jul; 49(13):3482-8. PubMed ID: 2786451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effect of MAb EMD 55900 depends on EGF-R expression and histopathology.
    Solbach C; Sterner-Kock A; Roller M; Schnürch HG; Stegmüller M; Caspar-Bell G; Schumm-Draeger PM; Kaufmann M; Knecht R
    Neoplasia; 2002; 4(3):237-42. PubMed ID: 11988843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of transforming growth factor-alpha (TGF-alpha) in basal and hormone-stimulated growth by estradiol, prolactin and progesterone in human and rat mammary tumor cells: studies using TGF-alpha and EGF receptor antibodies.
    Ahmed SR; Badger B; Wright C; Manni A
    J Steroid Biochem Mol Biol; 1991 Jun; 38(6):687-93. PubMed ID: 2064983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-EGF receptor monoclonal antibodies: biological studies and potential clinical applications.
    Mendelsohn J
    Trans Am Clin Climatol Assoc; 1989; 100():31-8. PubMed ID: 3077575
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.
    Harwerth IM; Wels W; Schlegel J; Müller M; Hynes NE
    Br J Cancer; 1993 Dec; 68(6):1140-5. PubMed ID: 7903153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cooperative inhibition of renal cancer growth by anti-epidermal growth factor receptor antibody and protein kinase A antisense oligonucleotide.
    Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; Pepe S; Bianco AR; Agrawal S; Mendelsohn J; Tortora G
    J Natl Cancer Inst; 1998 Jul; 90(14):1087-94. PubMed ID: 9672257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model.
    Buchsbaum DJ; Zhou T; Grizzle WE; Oliver PG; Hammond CJ; Zhang S; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3731-41. PubMed ID: 14506165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts.
    Goetsch L; Gonzalez A; Leger O; Beck A; Pauwels PJ; Haeuw JF; Corvaia N
    Int J Cancer; 2005 Jan; 113(2):316-28. PubMed ID: 15386423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy.
    Modjtahedi H; Moscatello DK; Box G; Green M; Shotton C; Lamb DJ; Reynolds LJ; Wong AJ; Dean C; Thomas H; Eccles S
    Int J Cancer; 2003 Jun; 105(2):273-80. PubMed ID: 12673691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells.
    Taetle R; Honeysett JM; Houston LL
    J Natl Cancer Inst; 1988 Sep; 80(13):1053-9. PubMed ID: 3261802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptors and EGF-responsiveness of the human breast-carcinoma cell line PMC42.
    Monaghan P; Ormerod MG; O'Hare MJ
    Int J Cancer; 1990 Nov; 46(5):935-43. PubMed ID: 2228321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.